Cargando…
Epigenetic Therapy of Cancer Preclinical Models and Treatment Approaches /
The growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders such as myeloid leukemias and preleukemias (myelodysplasias) is now being translated into treatment approaches that target the epigenetic defects pharmacologically. Such approaches include rea...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Berlin, Heidelberg :
Springer Berlin Heidelberg : Imprint: Springer,
2014.
|
| Edición: | 1st ed. 2014. |
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-642-38404-2 | ||
| 003 | DE-He213 | ||
| 005 | 20220117233635.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 131212s2014 gw | s |||| 0|eng d | ||
| 020 | |a 9783642384042 |9 978-3-642-38404-2 | ||
| 024 | 7 | |a 10.1007/978-3-642-38404-2 |2 doi | |
| 050 | 4 | |a RC254-282 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Epigenetic Therapy of Cancer |h [electronic resource] : |b Preclinical Models and Treatment Approaches / |c edited by Michael Lübbert, Peter A. Jones. |
| 250 | |a 1st ed. 2014. | ||
| 264 | 1 | |a Berlin, Heidelberg : |b Springer Berlin Heidelberg : |b Imprint: Springer, |c 2014. | |
| 300 | |a X, 325 p. 48 illus., 14 illus. in color. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a The fundamental role of epigenetic regulation for normal and disturbed all growth and differentiation -- Mouse models to study DNA methylation in cancer research -- Epigenetic regulation of normal hematopoietic development -- Epigenetic regulation of globin genes and disturbances in hemoglobinopathies -- DNA methylation abnormalities in hematopoietic disorders: biological significance and methodological approaches -- Epigenetic modifications mediated by the AML1/ETO and MLL leukemia fusion proteins -- Epigenetic abnormalities in lung cancer -- Pharmacodynamic Responses to DNA Methyltransferase Inhibition -- Histone Methyltransferases: Opportunities in Cancer Drug Discovery -- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy -- Clinical Implications of Epigenetic Alterations in Lung Cancer -- Epigenetic disturbances in colorectal cancer -- Epigenetic Therapies in Solid Tumours: from preclinical models to clinical trial results. | |
| 520 | |a The growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders such as myeloid leukemias and preleukemias (myelodysplasias) is now being translated into treatment approaches that target the epigenetic defects pharmacologically. Such approaches include reactivation of tumor suppressor genes and other antiproliferative genes by reversal of DNA hypermethylation through azanucleosides, and use of HDAC inhibitors to reverse gene silencing mediated by chimeric, leukemia-specific transcription factors. This book first presents the latest evidence derived from preclinical models regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail. | ||
| 650 | 0 | |a Oncology. | |
| 650 | 0 | |a Hematology. | |
| 650 | 0 | |a Medical genetics. | |
| 650 | 1 | 4 | |a Oncology. |
| 650 | 2 | 4 | |a Hematology. |
| 650 | 2 | 4 | |a Clinical Genetics. |
| 700 | 1 | |a Lübbert, Michael. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Jones, Peter A. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783642384035 |
| 776 | 0 | 8 | |i Printed edition: |z 9783642384059 |
| 776 | 0 | 8 | |i Printed edition: |z 9783662519288 |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-3-642-38404-2 |z Texto Completo |
| 912 | |a ZDB-2-SME | ||
| 912 | |a ZDB-2-SXM | ||
| 950 | |a Medicine (SpringerNature-11650) | ||
| 950 | |a Medicine (R0) (SpringerNature-43714) | ||